1
|
Hirsch FR, Varella-Garcia M and Cappuzzo
F: Predictive value of EGFR and HER2 overexpression in advanced
non-small lung cancer. Oncogene. 28:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sun M, Behrens C, Feng L, et al: HER
family receptor abnormalities in lung cancer brain metastases and
corresponding primary tumors. Clin Cancer Res. 15:4829–4837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Mounawar M, Mukeria A, Le Calvez F, et al:
Patters of EGFR, HER2, TP53, and KRAS mutation of p14arf expression
in non-small lung cancer in relation to smoking history. Cancer
Res. 67:5667–5672. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Shigematsu H, Takahashi T, Nomura M, et
al: Somatic mutations of the HER2 kinase domain in lung
adenocarcinomas. Cancer Res. 65:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Buttitta F, Barassi F, Fresu G, et al:
Mutational analysis of the HER2 gene in lung tumors from Caucasian
patients: mutations are mainly present in adenocarcinomas with
bronchioloalveolar features. Int J Cancer. 119:2586–2591. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Stephen P, Hunter C, Bignell G, et al:
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature.
431:525–526. 2004. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Wang SE, Narasanna A, Perez-Torres M, et
al: HER2 kinase domain mutation results in constitutive
phosphorylation and activation of HER2 and EGFR and resistance to
EGFR tyrosine kinase inhibitors. Cancer Cell. 10:25–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Li C, Fang R, Sun Y, et al: Spectrum of
oncogenic driver mutations in lung adenocarcinomas from east asian
never smokers. PLoS One. 6:e282042011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kaczanowski R, Trzeciak L and Kucharczyk
K: Multitemperature single-strand conformation polymorphism.
Electrophoresis. 22:3539–3545. 2001. View Article : Google Scholar : PubMed/NCBI
|
12
|
Sanger F, Nicklen S and Coulson AR: DNA
sequencing with chain terminating inhibitors. Proc Natl Acad Sci.
74:5463–5467. 1977. View Article : Google Scholar : PubMed/NCBI
|
13
|
Diaz R, Nguewa PA, Parrondo R, et al:
Antitumor and angiogenic effect of the dual EGFR and HER-2 tyrosine
kinase inhibitor lapatinib in a lung cancer model. BMC Cancer.
10:188–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shimamura T, Ji H, Minami Y, et al:
Non-small-cell lung cancer and Ba/F3 transformed cells harboring
the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific
epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Cancer Res. 66:6487–6491. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Reid A, Vidal L, Shaw H and de Bono J:
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J
Cancer. 43:481–489. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Li D, Ambrogio L, Shimamura T, et al:
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in
preclinical lung cancer models. Oncogene. 27:4702–4711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Perera SA, Li D, Shimamura T, et al:
HER2YVMA drives rapid development of adenosquamous lung tumors in
mice that are sensitive to BIBW2992 and rapamycin combination
therapy. Proc Natl Acad Sci USA. 106:474–479. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Shimamura T, Greulich H, Solca FF and Wong
KK: Efficacy of BIBW-2992, potent irreversible inhibitor of EGFR
and HER2 in human NSCLC xenografts in a transgenic mouse
lung-cancer model: C7–04. J Thorac Oncol. 2(suppl): S3802007.
|
19
|
Hirsh V: Afatinib (BIBW 2992) development
in non-small-cell lung cancer. Future Oncol. 7:817–825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
20
|
De Greve J, Teugels E, De Mey J, et al:
Clinical activity of BIBW2992, an irreversible inhibitor of EGFR
and HER2 in adenocarcinoma of the lung with mutations in the kinase
domain of HER2neu. J Thorac Oncol. 4:S307(abstr). 2009.PubMed/NCBI
|
21
|
Heinmöller P, Gross C, Beyser K, et al:
HER2 status in non-small cell lung cancer: results from patient
screening for enrollment to a phase II study of herceptin. Clin
Cancer Res. 9:5238–5243. 2003.PubMed/NCBI
|